Connor, Clark & Lunn Investment Management Ltd. Nuvation Bio Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $22 Billion
- Q2 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 363,925 shares of NUVB stock, worth $837,027. This represents 0.0% of its overall portfolio holdings.
Number of Shares
363,925
Previous 382,180
4.78%
Holding current value
$837,027
Previous $1.39 Million
23.65%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding NUVB
# of Institutions
151Shares Held
123MCall Options Held
9.7KPut Options Held
6.5K-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$44.2 Million1.98% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$37.3 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.3MShares$30.5 Million50.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$23.3 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA6.95MShares$16 Million6.22% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $500M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...